The majority of in-house counsel’s time and attention spent on contracts is often focused on the wording of the limitation-of-liability (LoL) clause. In the brave new world of big data, the significance of the LoL clause cannot be overstated. Although they cannot secure protection from all risks, they need not be leaky sieves.
California’s unique “toxic warning” law, Proposition 65, has been on<br />the books in the United States for 30 years, yet it continues to trap the unwary manufacturer and retailer and funnel millions of dollars to a cottage industry that seemingly exists for just one purpose: lining their pockets with your company’s hard-earned profits.
Learn about cutting-edge developments in compliance training (apps, multimedia, etc.) that can elevate your compliance program to the next level. Discover how your organization can leverage social media to bolster its compliance program. Squarely address “tone at the middle” and learn best practices for ensuring that middle managers – your first line of defense – are especially prepared to serve as good compliance stewards. Worried about whistleblowers? Examine techniques that foster communications within your organization, to help ensure that employee concerns are raised internally.
There are many actions that the other party may take during a negotiation that, whether inadvertent or intentional, can help delay or derail the process if you don't respond properly. Here is a second set of ten such scenarios, followed by some brief summary comments regarding how you may wish to respond in each instance.
SEC Amicus brief Pacific v. Mayer (PIMCO v REFCO) filed 8/6/09
The authors look to case law and the EEOC Guidance on Psychiatric Disabilities and the Americans with Disabilities Act to determine who is protected under the ADA.
The Corporate & Securities Law Committee and the Employment & Labor Law Committee of the Association of Corporate Counsel ("ACC") are pleased to have this opportunity to provide comments on behalf of ACC with respect to the proposed amendments to the proxy statement executive compensation disclosure rules which the Securties and Exchange Commission (the Commission) published in the Federal Register on February 8, 2006.
This Quick Overview addresses how the Precision Medicine Initiative (the "PMI") allows targeted therapies to be deployed that are more likely to be efficacious, less likely to lead to adverse side effects, and, in many circumstances, more cost-effective for both the patient and society at large than current approaches to many different illnesses.